1
Blue LED Light Therapy

What can I do
about my psoriasis?

To control psoriasis effectively, it is essential to understand the disease, its causes and what you can do to improve your quality of life.
We’re here to support you – so we can challenge psoriasis together.

Facts about psoriasis.

 

Psoriasis is a chronic autoimmune disease affecting the skin. Psoriasis plaques can occur on all parts of the body including your hands, feet, elbows, legs, torso and head.

 

Classification of psoriasis severity – mild, moderate and severe.

Plaque psoriasis is characterised as mild, moderate, or severe according to the amount of body surface area (BSA) affected and the severity of the symptoms such as redness, thickness, and scaling of the skin.7
125 million people worldwide are affected by plaque psoriasis

You are not alone. About 125 million people worldwide are affected by plaque psoriasis. 
About 10 in 100 people carry the genes that makes them more likely to get psoriasis

About 10 in every 100 people have genes that make them more likely to get psoriasis, but only two or three of them will actually develop plaque symptoms.

Understanding 
what happens to your skin.


With psoriasis, your skin can flare up with red and itchy patches. But why? And why now? There are many different triggers that can lead to psoriasis flare ups – but there is also a lot you can do to help ease your symptoms.  
 

Not sure of what to do? Talk to your dermatologist or doctor, they can help you find a way to reduce your symptoms. And for more help, you can visit the Philips Psoriasis Stop portal to catch up with the latest articles, tips and tricks on how to improve your psoriasis and general well-being in day-to-day life.

Choose the therapy that’s in tune with your life.


For years, mild to moderate plaque psoriasis has often been treated the same way. With ointments and creams or with UV radiation if patients don’t respond to other treatments. Now there’s a new way.

 

With Blue LED Light Therapy and Philips BlueControl1, we are introducing a whole new way to treat mild to moderate psoriasis – practically, gently and effectively2,3

Stay in touch with us.
On Social Media.

Like us on Facebook

At Philips, we want to improve the quality of people’s lives through meaningful innovation. Hearing from our customers is key to this mission and on Facebook, we welcome your insights, feedback and ideas.

Check out our Twitter feed

Philips is here to empower you to live an active and healthy life. We tweet tips and tricks to help improve your psoriasis and inform you on our latest news.

Check out our YouTube videos

Discover how Philips delivers innovation that matters to you. Watch our videos and see how Blue LED Light Therapy is changing the

way you experience psoriasis therapy.

Our psoriasis treatment products

  • BlueControl Advance

    BlueControl Advance

    • 15 minutes treatment per plaque
    • Wearable blue light therapy
    • Clinically proven efficacy
    • Without chemicals or cortisone
    Overall rating 4.6/ 5
    10
    PSK2103
    £349.00
    View product
  • BlueControl

    BlueControl

    • 30 minutes treatment per plaque
    • Wearable blue light therapy
    • Clinically proven efficacy
    • Without chemicals or cortisone
    Overall rating 3.6/ 5
    27
    PSK0202
    £259.00
    View product
  1. Philips BlueControl is an EU CE-marked class IIa  medical device (CE0344) for the treatment of mild to moderate plaque psoriasis (psoriasis vulgaris). The device is currently not available outside EU. Before altering or stopping any prescribed medication or using the device, patients should consult with their physicians and carefully read the instructions for use. July 2017.
  2. Weinstabl A et al. Dermatology. 2011; 223 (3): 251 – 9.
  3. Pfaff S et al. Dermatology. 2015; 231: 24 – 34.
  4. Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005; 352: 1899 – 912. 
  5. Gayathri K. Perera et al. Annu. Rev. Pathol. Mech. Dis. 2012; 7: 385 – 422.
  6. Ricketts JR, Rothe MJ, Grant-Kels JM. Clin Dermatol. 2010 (Nov-Dec); 28 (6): 615 – 26.
  7. Mrowietz U et al. Arch Dermatol Res. 2011 (Jan); 303 (1): 1 – 10.
  8. Jordan CT, Bowcock AM et al. The American Journal of Human Genetics. 2012 May 4; 90(5): 784 - 95.
  9. World Health Organization. Global Report on Psoriasis. 2016. See detailed information
  10. Gottlieb AB, Chao C, Dann F. J. Dermatol. Treat. 2008 19: 5 – 21.
  11. Davidovici BB et al. J. Investig. Dermatol. 2010; 130: 1785 – 96.
  12. Crow JM. Nature. 20 December 2012; 492: 50 – 51.
  13. Gattu S, et al. J Eur Acad Dermatol Venereol. 2009 Jan; 23(1): 36 – 41.